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24 The Journal of Thoracic and Cardiobjectives: Diabetes is an important predictor of morbidity and mortality after
ardiac surgery, but the reason is unclear. The aims of these studies, therefore, were
o elucidate whether cell death is greater in ischemic and nonischemic diabetic
uman myocardium than in nondiabetic myocardium and to investigate the under-
ying mechanism.
ethods: The right atrial appendages (n  8 per group) of patients without diabetes
nd patients with type 1 and 2 diabetes were subjected to 90 minutes of simulated
schemia and 120 minutes reoxygenation. Tissue injury was measured by the release
f creatine kinase into the media, and cellular apoptosis and necrosis were assessed
n tissue by the terminal transferase deoxyuridine triphosphate nick-end labeling
ssay and propidium iodide staining. Initiator and effector caspases activations were
lso measured.
esults: Apoptosis and necrosis were greater in the type 2 and type 1 diabetes
roups than in the nondiabetes group both in fresh tissue and after simulated
schemia–reoxygenation. Activation of effector caspases was also higher in the
iabetes groups than in the nondiabetes group after simulated ischemia–reoxygen-
tion. Caspase-3 inhibition reduced apoptosis in all study groups without influenc-
ng necrosis; however, poly–adenosine diphosphate–ribose polymerase inhibition
esulted in a similar reduction in apoptosis and in necrosis in all groups, whereas
aspase-2 inhibition did not.
onclusions: Diabetes increases both apoptosis and necrosis in human myocardium,
oth fresh and after being subjected to ischemia–reoxygenation, an effect that is
ediated, at least in part, by caspase-3 and poly–adenosine diphosphate–ribose
olymerase activation. These results may explain the increased cardiac-related
orbidity and mortality associated with cardiac surgery in patients with diabetes.
iabetes is associated with an increased risk of cardiac complications in
patients with coronary atherosclerosis1 and is also an important predictor of
morbidity and mortality after cardiac surgery.2 Myocardial injury caused by
schemia and reperfusion during cardiac surgery may induce cell death, which is
onsidered to be an important determinant in the development of left ventricular
ysfunction and heart failure in ischemic cardiomyopathy.3 Animal studies have
emonstrated that loss of myocytes as a result of necrosis leads to wall restructuring,
ide-to-side slippage of cells, mural thinning, chamber dilation, fibroblast activation,
nd myocardial scarring, which in turn result in depression of ventricular function.4
t is possible that diabetes may exacerbate these changes by increasing apoptosis and
ecrosis. Although patients with this condition are at an increased risk for ischemic
vents,5-7 the susceptibility of the diabetic myocardium to ischemic injury is
vascular Surgery ● July 2007
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Pontroversial in the literature on animal studies,5,6,8,9 and
he subject remains largely unexplored in human beings (for
eview see Galiñanes and Fowler10).
Caspases are a large protein family of cysteine proteases
hat have been specifically linked with apoptosis, and their
nhibition has been shown to attenuate apoptosis and myo-
ardial ischemic injury in nondiabetic rats11; however, the
ole of caspases in ischemic injury of the diabetic myocar-
ium is unknown. More recently, poly–adenosine diphos-
hate–ribose polymerase (PARP), a nuclear protein that
lays an essential role in DNA damage and repair, has also
een shown to be linked to tissue damage in various patho-
ogic conditions and to be associated with oxidant stress
ccurring in myocardial ischemic injury,12,13 stroke,14 and
irculatory shock.15 It might be expected that PARP inhi-
ition would reduce myocardial ischemic injury; however,
he role of PARP in the presence of pathologic conditions
uch as diabetes needs to be clarified.
The first aim of these studies performed on the human
yocardium was to elucidate the effect of diabetes on the
egree of cell death by apoptosis and necrosis in both
onischemic and ischemic tissue. In addition, the roles
layed by caspases and PARP activation in ischemia reper-
usion–induced cell death were investigated.
aterials and Methods
atients
he right atrial appendages from patients undergoing elective
oronary artery bypass grafting were retrieved at the time of right
trial cannulation. For this, local ethical approval and patients’
nformed consent were obtained (Leicestershire Research Ethics
ommittee reference No. 7805). Patients with and without diabe-
es (n  8 per group) undergoing elective cardiac surgery were
ncluded in the study. Patients with atrial fibrillation, poor ejection
raction (30%), or mitral or tricuspid valve pathology; those
aking potassium channel openers (nicorandil or diazoxide); and
hose undergoing emergency cardiac surgery were excluded.
lood glucose levels were well controlled before surgery in the
articipants with type 1 or type 2 diabetes mellitus, and they were
ept within the physiologic range during surgery in all study
Abbreviations and Acronyms
AFC  7-amino-4-trifluoromethyl coumarin
CK  creatine kinase
MTT  3-[4, 5 dimethylthiazol-2-y1]-2, 5-
diphenyltetrazolium bromide
PARP  poly–adenosine diphosphate–ribose
polymerase
PI  propidium iodide
SIR  simulated ischemia–reoxygenation
TUNEL terminal transferase deoxyuridine
triphosphate nick-end labelingatients, both with and without diabetes. T
The Journal of Thoracicxperimental Preparation and Solutions
he sectioning of the atrial muscle and the simulated ischemia–
eoxygenation (SIR) preparation have been previously described.16
riefly, the atrial muscles were immersed in cold (4°C) buffer
olution and transferred within 2 minutes from the operating
heater to the laboratory. The appendages were then mounted onto
ground glass plate with the epicardial surface face down and then
liced freehand with surgical skin graft blades (Swann-Morton Ltd,
heffield, UK) to a thickness between 300 and 500 m. The
uscles (weight 30–50 mg) were transferred to conical flasks
25-mL Erlenmeyer flasks; SCHOTT Jenaer Glas GmbH, Jena,
ermany) containing 10 mL oxygenated buffered solution (com-
osition listed later), and the flasks were placed in a shaking water
ath maintained at 37°C. After this, the muscles were equilibrated
or 30 minutes in oxygenated (95% oxygen/5% carbon dioxide)
rebs–Henseleit N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
cid buffered solution containing the following: 118-mmol/L so-
ium chloride, 4.8-mmol/L potassium chloride, 27.2-mmol/L so-
ium hydrogen carbonate, 1.2-mmol/L magnesium chloride, 1.0-
mol/L potassium dihydrogen phosphate, 1.20-mmol/L calcium
hloride, 10-mmol/L glucose, and 20-mmol/L N-2-hydroxyeth-
lpiperazine-N-2-ethanesulfonic acid at a pH of 7.4. The buffer
as supplemented with 10% fetal calf serum (Harlan SeraLabs No.
-0001A; Harlan Bioproducts for Science, Inc, Indianapolis, Ind).
or the induction of simulated ischemia, the media were bubbled
ith 95% nitrogen/5% carbon dioxide (pH 6.80–7.00) in the
bsence of glucose.
xperimental Protocols
Study 1: Degree of apoptosis and necrosis in nonischemic
resh diabetic myocardium. Apoptosis, necrosis, and initiator (in-
luding caspases-2, 8, 9, and 10) and effector caspase (in-
luding caspases 3, 6 and 7) activations were assessed in
onischemic fresh atrial muscles from patients without diabetes
nd from those with type 1 and 2 diabetes (n  8 per group).
Study 2: Effect of ischemia–reoxygenation in diabetic myo-
ardium. The atrial muscles (n  8/group) from patients without
iabetes and with type 1 and 2 diabetes were equilibrated for 30
inutes and then subjected to the following two experimental
rotocols: aerobic perfusion for 210 minutes and 90 minutes of
imulated ischemia followed by 120 minutes of reoxygenation
SIR). Creatine kinase (CK) release was measured in the incuba-
ion media during the 120 minutes of reoxygenation, or during the
ast 120 minutes of aerobic incubation in the control preparations,
nd the tissue was taken at the end of protocols for the assessment
f tissue viability, cellular apoptosis and necrosis, and initiator and
ffector caspase activations.
Study 3: Roles of caspases and PARP in cell death in diabetic
yocardium. Sections of atrial muscle (n  6) from patients
ithout diabetes and those with type 1 and 2 diabetes were
quilibrated for 30 minutes and then subjected to the following
rotocols: aerobic perfusion for 210 minutes, 90 minutes of sim-
lated ischemia followed by 120 minutes of reoxygenation (SIR),
IR with the caspase-3 inhibitor z.DEVD.fmk (70 nmol/L), SIR
ith different concentrations of the caspase-2 inhibitor z.VDVAD-
fmk (0, 0.02, 0.2, and 2 mol/L), and SIR with different concen-
rations of the PARP inhibitor PJ-34 (0, 0.07, 0.7, and 7 mol/L).
he caspase and PARP inhibitors were incubated with the muscles
and Cardiovascular Surgery ● Volume 134, Number 1 125
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CSPor the entire experimental period. As in the previous protocol, CK
elease was measured in the incubation media and cellular apo-
tosis and necrosis were assessed in the muscles at the end of the
rotocols.
ssessment of Tissue Injury and Viability
K release into the perfusate during the 120 minutes of reoxygen-
tion was measured as an index of tissue injury. The enzyme
ctivity was measured with a linked-enzyme kinetic assay accord-
ng to manufacturer instruction (DG147-K; Sigma Chemicals Pty
td, Perth, Australia) and expressed as international units per gram
f wet weight.
Tissue viability was assessed by the mitochondrial reduction of
-[4, 5 dimethylthiazol-2-y1]-2, 5-diphenyltetrazolium bromide
MTT) to an insoluble purple formazan dye (M2128; Sigma Chem-
cals).17 The absorbance of the blue formazan product was measured
n a plate reader (Benchmark; Bio-Rad Laboratories Inc, Hercules,
alif) at 550 nm, and the results were expressed as micromol of
ormazan per gram of wet weight. A reduction in the MTT values was
onsidered to represent decreased tissue viability.
ssessment of Apoptosis and Necrosis
irst, the muscles were incubated for 10 minutes on ice with
-mol/L propidium iodide (PI) in 0.1-mol/L trisodium citrate and
0-mmol/L phosphate-buffered saline solution at pH 7.4 to iden-
ify the necrotic nuclei. Sections were then fixed twice, initially for
0 minutes with 4% paraformaldehyde in 30% sucrose and then
ith 20-mmol/L phosphate-buffered saline solution overnight on
ce at pH 7.4. After this, serial 10-m sections were cut with a
right cryomicrotome (model OTF; Bright Instrument Co Ltd,
untingdon, UK) at 25°C in tissue-embedding matrix (Tissue
ek OCT compound; Sakura Finetek USA, Inc, Torrance, Calif).
he cryopreserved tissue sections were washed with 20-mmol/L
hosphate-buffered saline solution at pH 7.4 for 2 minutes, then
ade permeable in 0.02-mg/mL proteinase K for 10 minutes at
7°C and presensitized for 1 minute in a microwave oven at 800 W
n 0.1% Triton X-100 (The Dow Chemical Company, Midland,
ich) and 0.1-mol/L sodium citrate at pH 6.0. To assess apoptosis,
erminal deoxynucleotidyl transferase was used to incorporate
eoxyuridine triphosphate oligonucleotides labeled with fluores-
ein isothiocyanate to DNA strand breaks at the 3=-OH termini in
template-dependent manner (terminal transferase deoxyuridine
riphosphate nick-end labeling [TUNEL] assay) with a commer-
ially available kit (1684795; Roche Diagnostics Division, Basel,
witzerland). With this labeling procedure sequence, the nuclei
ould be stained either with PI or by TUNEL but not both. An
-m section of the mirror specimens opened up the cellular
embrane of all the cells to enable all the nuclei to be stained.
efore the TUNEL labeling of muscles, positive control specimens
ere treated with DNase I, and negative control specimens were
btained by adding the label solution of the kit without the enzyme
olution. The fluorescein isothiocyanate fluorescence emission
range 600–630 nm) was measured with argon-ion fluorescence
xcitation at 488 nm and detected by laser confocal epifluores-
ence microscopy with a 10 oil-immersion objective. The PI-
abeled nuclei were excited with helium–neon laser light at 543
m, and fluorescence was detected at an emission range of 680 to
30 nm to abolish fluorescence bleed through from fluorescein o
26 The Journal of Thoracic and Cardiovascular Surgery ● Julysothiocyanate–labeled nuclei. Analysis was done with National
nstitutes of Health Image software (Scion Corporation, Frederick,
d) with the Cavalieri-3 macro (G. MacDonald, University of
ashington, Seattle, Wash), which allows placement of point-
ounting templates over an image to perform stereologic estimates.
luorescent signals with areas greater than 16 m2 were counted
o ensure that only nuclei were taken into account and to avoid the
nclusion of artifact. Absolute numbers of green fluorescent apo-
totic and necrotic red fluorescent nuclei in any given image field
ere determined by dividing by the total number of PI-labeled
uclei in the next serial or mirror section. The absolute percentage
f apoptotic cells was given by dividing apoptotic nuclei by total
I-labeled nuclei and multiplying by 100%, whereas the percent-
ge of necrotic cells was obtained by dividing necrotic nuclei by
otal PI-labeled nuclei and multiplying by 100%. The automatic
ounting was combined with regular manual inspection to ensure
hat artifacts were not represented in the data.
easurement of Caspase Activities
he muscle sections that had been stored at 800°C until analysis
ere thawed in 400 L cell lysis buffer (100 mmol/L N-2-
ydroxyethylpiperazine-N-2-ethanesulfonic acid, 10% sucrose,
.1% 3-[3-(cholamidopropyl)dimethylammonio]-1-proanesulfon-
te, and 10-mmol/L dithiothreitol) in the presence of a cocktail of
nzyme inhibitors (P2850; Sigma Chemicals) at a pH of 7.0 to
elease the intracellular contents. The muscle was diced finely and
hen homogenized (Ultra-Turrax homogenizer; Janke & Kunkel
mbH & Co, Staufen, Germany) at 13,000 rpm for 1 minute on
ce. This was followed by centrifugation (PK121R; ALC Interna-
ional, Cologno Honzese, Italy) at 14,000 rpm for 30 minutes.
ubsequently, the protein concentration of the soluble supernatant
cellular lysate) was measured with a detergent-compatible Bio-
ad assay (23225; Pierce & Warriner [UK] Ltd, Chester, UK).
liquots of cellular lysate were then tested for caspase activity by
he addition of a caspase-specific peptide or substrate, D(OMe)-
(OMe)-V-D(OMe) (DEVD), conjugated to the chromophore (flu-
rescent reporter molecule) 7-amino-4-trifluoromethyl coumarin
AFC). The cleavage of the peptide DEVD from DEVD.AFC
final concentration 20 mol/L; Alexis Corporation, San Diego,
alif) releases AFC, which when excited by light at 400 nm emits
uorescence at 505 nm. The level of caspase activity in the cellular
ysate was detected by fluorescence signal obtained with a flu-
rometer (FLUOstar P401; BMG LABTECH GmbH, Offenburg,
ermany). The amount of caspase-3–like activity was measured
y using the effector caspase inhibitor z.DEVD.fmk at a final
oncentration of 10 mol/L in the well of the reader plate and by
ubtracting the fluorescence obtained by the total fluorescence
easured in the absence of the inhibitor. The results were ex-
ressed as arbitrary units of fluorescence activity per gram of wet
eight.
hemicals
he caspase-2 inhibitor z.VDVAD.fmk (FMK003; R&D Systems,
inneapolis, Minn) was used at different concentrations (0, 0.02, 0.2,
nd 2 mol/L). The caspase-3 inhibitor z.DEVD.fmk (FMK004) was
sed at the concentration of 70 nmol/L, which was shown to be the
ptimal dose by previous experiments in our laboratory.18 The PARP
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Pnhibitor PJ-34 (L10210; Alexis Corporation) was also used at differ-
nt concentrations (0, 0.07, 0.7, and 7.0 mol/L).
tatistical Analysis
ll results are expressed as mean  SEM. To compare the overall
tatistical significance among no diabetes and type 1 and 2 diabetes
roups, the nonparametric analysis of variance (Kruskal–Wallis H)
echnique was used. The comparisons between the independent
roups are based on nonparametric Mann–Whitney test.
esults
tudy 1: Degree of Apoptosis and Necrosis in
onischemic Fresh Diabetic Myocardium
Apoptosis and necrosis. Figure 1 shows that cell death
n nonischemic fresh myocardium was significantly higher
n the type 1 and 2 diabetes groups than in the nondiabetes
roup. Thus, whereas apoptosis percentages were 12.5% 
.9% and 15.0%  2.8% in the type 1 and 2 diabetes
roups, respectively, the value was 3.7%  0.8% (P  .05)
n the nondiabetes group. Similarly, the mean values for
ecrosis were 10.7%  2.9% in the type 2 diabetes group
nd 10.3%  2.0% the in type 1 diabetes group but only
.0% 1.1% in the nondiabetes group (P  .05). Figure E1
hows representative images for apoptosis and necrosis in
resh myocardium from the three study groups. It should be
oted that although some of the observed cell death in the
trial muscles could be attributed to the trauma of tissues
igure 1. Percentages of apoptosis and necrosis (n  8/group) in
onischemic fresh myocardial tissue from patients without dia-
etes (ND), with type 2 diabetes (NIDDM), and with type 1
iabetes. Asterisk indicates P < .05 versus nondiabetes group.nduced by the procurement procedure, all muscles were n
The Journal of Thoracicreated identically, and the differences seen between the
iabetes and nondiabetes groups are therefore real.
Caspase activities. As shown in Figure 2, the activities of
nitiator caspases in fresh nonischemic muscles was similar in
ondiabetes and type 1 and 2 diabetes groups. The activity of
ffector caspases, however, was significantly increased in the
ype 1 and 2 diabetes groups relative to the nondiabetes group.
tudy 2: Effect of Ischemia–Reoxygenation in Diabetic
yocardium
Apoptosis and necrosis. Figure 3 (A and B) show that
poptosis and necrosis were increased in time-matched aero-
ically incubated muscles for 210 minutes in the type 1 and 2
iabetes groups relative to the values in the nondiabetes group,
onfirming the results in fresh (not incubated) tissue. The
imilar degrees of apoptosis and necrosis seen in fresh and
erobically incubated muscles rules out a significant effect of
he tissue culture conditions on these two end points. The
gures also show that SIR caused significant increases in the
wo forms of cell death in the nondiabetes group and that
alues were even greater in the type 1 and 2 diabetes groups.
igure E2 shows representative images for apoptosis and ne-
rosis after ischemia–reoxygenation for the three study groups.
t is worth noting that the degrees of apoptosis and necrosis in
erobically incubated and SIR-treated muscles were similar for
he two types of diabetes; because of this lack of distinction, no
eparation into groups of patients with types 1 and 2 diabetes
as performed in study 3.
CK release. Table E1 demonstrates that the mean CK
elease values during the first 2 hours of reoxygenation and
fter 90 minutes of ischemia were similarly increased in the
igure 2. Caspase activation in fresh myocardial tissue and in
uscles after ischemia–reoxygenation (n  8 per group) from
atients without diabetes (ND), with type 2 diabetes (NIDDM),
nd with type 1 diabetes (IDDM). Asterisk indicates P < .05
ersus nondiabetes group; dagger indicates P < .05 versus cor-
esponding fresh tissue group. AU, Arbitrary units.ondiabetes and diabetes groups.
and Cardiovascular Surgery ● Volume 134, Number 1 127
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CSPMTT reduction. Table E2 shows that SIR resulted in a
ignificant decrease in MTT reduction in the nondiabetes and
iabetes groups. In contrast with the results on apoptosis and
ecrosis, this decrease was of similar degree in all three groups.
Caspase activities. Figure 2 shows that SIR induced a
igure 3. Percentages of apoptosis (A) and necrosis (B) after
imulated ischemia–reoxygenation (n  8 per group) in cardiac
uscles from patients without diabetes (ND),with type 2 diabetes
NIDDM), and with type 1 diabetes (IDDM). Asterisk indicates P<
05 versus nondiabetes group; dagger indicates P < .05 versus
orresponding aerobic control group.ignificant increase in initiator caspase activity in atrial i
28 The Journal of Thoracic and Cardiovascular Surgery ● Julyuscles from the three groups of patients relative to fresh
issue. SIR did not significantly influence the activity of the
ffector caspases in the muscles from patients without dia-
etics, but this activity was greatly elevated in the type 1
nd 2 diabetes groups.
tudy 3: Role of Caspases and PARP in Cell Death in
iabetic Myocardium
Apoptosis and necrosis. Figure 4 (A and B) shows that
n the presence of the caspase-3 inhibitor z.DEVD.fmk the
poptosis caused by SIR was almost completely abolished
n the nondiabetes group, but necrosis was unaffected. In
ontrast, in the muscles from patients with diabetes,
aspase-3 inhibition reduced apoptosis by only 50%, al-
hough also without effect on necrosis.
Table E3 shows that the percentages of apoptosis and
ecrosis in atrial tissue subjected to SIR from patients
ith and without diabetes was not affected by the pres-
nce of various concentrations of the caspase-2 inhibitor
.VDVAD.fmk.
Figure 5 (A and B) shows that the percentages of apo-
tosis and necrosis in atrial tissue subjected to SIR were
imilarly reduced in nondiabetes and diabetes groups in a
ose-dependent manner by the PARP inhibitor PJ-34. Sig-
ificant reductions were obtained at concentrations of 0.7
mol/L for apoptosis and 7 mol/L for necrosis.
CK release. Table E4 shows that the release of CK after
IR was not significantly affected by the caspase-3 and
aspase-2 inhibitors z.DEVD.fmk and z.VDVAD.fmk. In
ontrast, PARP inhibition resulted in a significant reduction
n CK release. These results taken together may suggest that
K release is a reflection of necrosis rather than apoptosis.
iscussion
hese studies demonstrate that cell death by apoptosis and
ecrosis is greater in the human fresh, nonischemic myo-
ardium of patients with diabetes than without diabetes, and
hat this is associated with increased expressions of effector
aspases. They also show that diabetic myocardium is more
usceptible to ischemia–reoxygenation injury than is non-
iabetic tissue, an effect is mediated at least in part by
aspase-3 and PARP activation. The importance of these
ndings for the understanding of the pathophysiology of
schemia–reoxygenation injury in the diabetic myocardium
nd their clinical implications are discussed here.
ell Death in Fresh, Nonischemic Diabetic
yocardium
ell death by apoptosis and necrosis is a feature of end-
tage heart failure,19 but it also occurs in the healthy myo-
ardium.20 Here we have demonstrated that the occurrence
f apoptosis and necrosis in human atrial tissue are greater
n patients with diabetes than without diabetes, a finding
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Pupported by those of Frustaci and colleagues21 in ventric-
lar biopsies. Because myocytes rarely proliferate in adult
ardiac muscles, the increased loss of cardiac muscles in the
iabetic myocardium may lead to a reduction in cardiac
ass and to elevated interstitial and perivascular fibrosis,
ausing a decrease in myocardial performance and ventric-
igure 4. Percentages of apoptosis (A) and necrosis (B) in myo-
ardial tissue from patients with and without diabetes (n  6 per
roup) subjected to ischemia–reoxygenation with and without
aspase-3 inhibitor (70-nmol/L Z.DVAD.fmk). Asterisk indicates P
.05 versus group without caspase-3 inhibition.lar dilatation, a sequence of events that may be responsible o
The Journal of Thoracicor the increasing cardiovascular mortality and morbidity in
atients with diabetes.22
A possible explanation for the increase in cell death in
atients with diabetes may be a greater oxidative stress
igure 5. Percentages of apoptosis (A) and necrosis (B) in myo-
ardial tissue from patients with and without diabetes (n  6 per
roup) subjected to ischemia–reoxygenation with various con-
entrations of PARP inhibitor (PJ-34). Asterisk indicates P < .05
ersus control group.bserved with this condition,23 which in turn may be re-
and Cardiovascular Surgery ● Volume 134, Number 1 129
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CSPponsible for the activation of effector caspases seen in our
tudies. There is experimental evidence that caspases are
ctivated in diabetes11 and also that caspases are activated
y oxidative stress in both patients without20 and with24
iabetes. Indeed, high glucose causes oxidative stress that
esults in caspase-3 activation in human endothelial cells
hrough stress activated protein kinase/c-Jun NH2-terminal
inases activation.25 Activating of effector caspases in dia-
etes can also be induced by the abnormal accumulation of
-hydroxyl fatty acid, as seen in mice, which alters the
ermeability of the mitochondrial membrane and causes the
elease of cytochrome c and the activation of the down-
tream caspases.26 Our findings that effector caspases are
ctivated in the fresh, nonischemic human atrial myocar-
ium suggests a central role of these proteins in the increase
n apoptosis seen in the hearts of patients with diabetes. It is
lear, however, that further investigation is required to
lucidate the precise molecular mechanism involved.
usceptibility of Diabetic Myocardium to Ischemia–
eoxygenation Injury
hese studies also show that diabetic myocardium is more
usceptible to ischemia–reoxygenation injury than is non-
iabetic myocardium when the PI and TUNEL techniques
o test for apoptosis and necrosis are used. These results in
he human myocardium are supported by experimental an-
mal studies in rats27 and dogs28 showing that diabetes
akes the heart more susceptible to ischemia–reoxygen-
tion injury. Other experimental studies,29 however, have
hown diabetic myocardium in fact to be more tolerant to
njury than nondiabetic tissue. The reasons for these diver-
ent results are not clear, but it is possible that duration and
everity of the diabetic state and differences in the experi-
ental preparations used may be involved.10 Another po-
ential explanation could be a lack of correspondence be-
ween different end points, as shown by our studies of CK
elease and MTT reduction.
The observation that the activity of the effector caspases
s more elevated in diabetic than nondiabetic myocardium in
esponse to an ischemic insult suggests that this class of
nzymes is responsible for the greater occurrence of apo-
tosis in diabetes. Caspase-3 inhibition reduced apoptosis in
iabetic myocardium to a lesser extent than in nondiabetic
yocardium, however, and inhibition of caspase-2, an en-
yme that shares sequence homology with initiator caspases
ike caspase-9 and 130 but has cleavage specificity closer
o the effector caspases caspase-3 and 7,31 did not effect
poptosis in either groups, suggesting that the increase of
yocardial apoptosis in diabetes is not dependent on greater
ctivation of the effector caspases alone. Our finding that
he induction of apoptosis by ischemia–reoxygenation in
uman nondiabetic myocardium is caspase-3 dependent is
upported by in vivo animal experimental studies11; how-
ver, the finding that caspase-3 inhibition only partially
30 The Journal of Thoracic and Cardiovascular Surgery ● Julyeduced apoptosis in diabetic myocardium suggests that a
aspase-independent pathway causing apoptosis also exist
n the diabetic myocardium.
In contrast with the results on inhibition of caspases-3
ctivity, the inhibition of PARP similarly reduced apoptosis
n a dose-dependent manner in both diabetic and nondia-
etic ischemic myocardium, with almost complete abolition
t the highest concentration of the inhibitor used (7-mol/L
J-34). This suggests that both caspase-dependent and -in-
ependent pathways of apoptosis converge in activation of
ARP. It is possible that the reported increase activation of
ARP seen in the diabetic rat myocardium32 is responsible
or the greater susceptibility of this tissue to apoptosis. The
ole of PARP in ischemic injury has been disputed, how-
ver, and whereas in vitro33 and in vivo13 studies have
emonstrated limitation of cellular injury by PARP inhibi-
ion, other investigators have suggested that PARP activa-
ion is not indispensable to apoptosis.30,34
onclusions
hese studies demonstrate molecular mechanisms by which
he diabetic myocardium is more susceptible than nondia-
etic tissue to ischemic injury. These findings may be of
linical relevance, because they provide an explanation for
he increased cardiac-related morbidity and mortality during
eart surgery seen in patients with diabetes and because
schemic injury can be reduced by pharmacologic manipu-
ation of the pathways involved. It should be remembered,
owever, that our studies were performed in vitro with atrial
yocardium and that any extrapolation to the clinical situ-
tion should be done with caution. An additional limitation
f these studies is that the cellular type of each nucleus
ndergoing death could not be determined because of meth-
dologic constraints. Therefore the observed cell death
ould be due to the demise of any cellular type within the
yocardium, including the cardiomyocyte.
We are grateful to Dr A. Fowler for the technical advice and to
rs N. Harris for secretarial help. We also thank Dr Sanjoy K.
aul for his help with the statistical analysis.
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CSPFigure E1. Representative images of apoptosis (green) and necrosis (red) in nonischemic fresh myocardial tissue
from patients without diabetes, with type 2 diabetes (NIDDM), and with type 1 diabetes (IDDM).31.e1 The Journal of Thoracic and Cardiovascular Surgery ● July 2007
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PFigure E2. Representative images of apoptosis (green) and necrosis (red) in myocardial tissue from patients
without diabetes, with type 2 diabetes (NIDDM), and with type 1 diabetes (IDDM) after 90 minutes of ischemia and
120 minutes of reoxygenation.T
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Aerobic control
Simulated
ischemia–reoxygenation
ondiabetes 0.79 0.07 1.96 0.14
ype 1 diabetes 0.63 0.08 2.12 0.14
ype 2 diabetes 0.69 0.07 1.98 0.15
ata are mean  SEM expressed as international units per milligram of
et weight in time-matched aerobic control samples (n  5) and samples
aken after 90 minutes of simulated ischemia and 120 minutes of reoxy-
enation from cardiac muscles from patients without diabetes and patients
ith types 1 and 2 diabetes mellitus. For all comparisons of simulatedschemia–reoxygenation versus aerobic control, P  .05.
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CSPABLE E2. Mean values for 3-[4, 5 dimethylthiazol-2-y1]-2,
-diphenyltetrazolium bromide reduction
Aerobic control
Simulated
ischemia–reoxygenation
ondiabetes 0.13 0.02 0.05 0.04
ype 1 diabetes 0.16 0.02 0.03 0.01
ype 2 diabetes 0.15 0.24 0.05 0.02
ata are mean  SEM expressed as international units per milligram of
et weight in time-matched aerobic control samples (n  5) and samples
aken after 90 minutes of simulated ischemia and 120 minutes of reoxy-
enation from cardiac muscles from patients without diabetes and patients
ith types 1 and 2 diabetes mellitus. For all comparisons of simulatedschemia–reoxygenation versus aerobic control, P  .05.ABLE E3. Percentages of apoptosis and necrosis in myocardial tissue from patients with and without diabetes
Caspase-2 inhibitor Z.VDVAD.fmk
0 mol/L 0.02 mol/L 0.2 mol/L 2 mol/L
poptosis (% of nuclei)
No diabetes 14.5 4.3 15.1 4.8 10.5 3.1 11.3  4.3
Diabetes 34.0 5.2 27.0 2.5 30.7 7.6 30.2  8.0
ecrosis (% of nuclei)
No diabetes 18.6 1.7 19.7 6.4 23.4 2.9 23.3  6.3
Diabetes 36.7 5.8 25.7 3.5 36.2 6.3 34.4  5.3
ata are mean  SEM. Tissues were subjected to 90 minutes of simulated ischemia and 120 minutes of reoxygenation in the presence of various
oncentrations of the caspase-2 inhibitor Z.VDVAD.fmk (n  6 per group).ABLE E4. Effects of the caspase-3 inhibitor z.DEVD.fmk (70 nmol/L), the caspase-2 inhibitor Z.VDVAD.fmk (2 mol/L), and
he poly–adenosine diphosphate–ribose polymerase inhibitor PJ-34 (7 mol/L) on creatine kinase release
SIR alone SIR plus inhibitor
aspase-3 inhibitor
No diabetes 2.92 0.72 2.51 0.96
Diabetes 2.67 0.59 2.79 0.32
aspase-2 inhibitor
No diabetes 2.53 0.19 2.38 0.24
Diabetes 2.76 0.94 2.52 0.81
oly–adenosine diphosphate–ribose polymerase inhibitor
No diabetes 2.88 0.25 1.48 0.15*
Diabetes 2.98 0.17 1.61 0.19*
ata are mean SEM expressed as international units per milligram of wet weight in samples taken after 90 minutes of simulated ischemia and 120 minutes
f reoxygenation from cardiac muscles from patients with and without diabetes (n 6 per group). SIR, Simulated ischemia–reoxygenation. *P .05 versus
imulated ischemia–reoxygenation alone.
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